CABOTEGRAVIR / CABOTEGRAVIR AND RILPIVIRINE

Brand name:

• Cabenuva®

Pharmaceutical company:

Viiv Healthcare Pty Ltd

Condition/indication:
(therapeutic use)

• Human Immunodeficiency virus (HIV)

PBAC Submission type:

New listing (Major Submission)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2021

Related medicines:

--

Submission received for:

March 2021 PBAC meeting

Opportunity for consumer comment:

Open 23/12/2020 and close 10/02/2021 (see PBS Website)

PBAC meeting:

Held on 10/03/2021

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---